Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by 99942Apophis on Sep 06, 2021 6:19am

Patient #19

Patient #19 announced in news release dated May 28 plus 90 days +7 days puts him/her into this week although I don't expect CR to be announced for one patient. Also patient #20 was announced June 11 plus 90 days + 7 days puts that patient into the week of Sept 20, perhaps but not guaranteed Theralase might announce results of those 2 patients. This new interim CEO seems to be more shareholder friendly.
Comment by StevenBirch on Sep 06, 2021 9:26am
I agree about the new interim CEO, maybe we'll even get more frequent updates but if not at least the tone seems to have changed. And now that summer is over the next few months should be interesting.
Comment by Oilminerdeluxe on Sep 06, 2021 11:05am
Well, I am sure there will be a few updates in the next quartely update
Comment by 99942Apophis on Sep 06, 2021 11:40am
Honestly Oilminerdeluxe because this recent 2nd Quarter Newsletter was late I forgot we are still due for sometime early October on the 3rd Quarter newsletter so yeah patients 19 & 20 will probably be included on that updated report.
Comment by Oilminerdeluxe on Sep 06, 2021 12:23pm
Maybe they will wait 3 months from this latest one? I guess we will see. At least people are a bit more positive these days on the board. Some excitement is always welcome. Really am eager to see the next results.
Comment by patience69 on Sep 06, 2021 12:31pm
I still can't help but wonder how long we will have to wait to hear where the money for the next indications is coming from. They are looking so good but we all know we can't go it alone , at least not with our current finances
Comment by Yajne on Sep 06, 2021 1:04pm
...like maybe partner(s) for the next indication or two? NSCLC and GBM appear more or less ready for their Ph1b launch. IMO there's a reason they've updated the corporate deck at this time. Hmmm
Comment by Oilminerdeluxe on Sep 06, 2021 1:17pm
Would like to know that too. Maybe Santa will be nice this year.
Comment by 99942Apophis on Oct 03, 2021 6:21am
99942Apophis wrote Patient #19 announced in news release dated May 28 plus 90 days +7 days puts him/her into week of Sept 6 although I don't expect CR to be announced for one patient. Also patient #20 was announced June 11 plus 90 days + 7 days puts that patient into the week of Sept 20, perhaps but not guaranteed Theralase might announce results of those 2 patients. This new interim CEO seems ...more  
Comment by Oilminerdeluxe on Oct 03, 2021 6:36am
That's how far I got. The rest is what I wish to know. I think/hope 3 or 4 patients could be enough for them to reveal for us. 
Comment by 99942Apophis on Oct 03, 2021 6:47am
Sure thing Oilminerdeluxe patients 21, 22, 23 & 24 were announced in Newsletter of Aug 30 plus 90 days + 7 days puts them into 2nd week of Dec., just in time for our Xmas gift. We can all join in for the singing of We Wish You a Merry Xmas. Oilminerdeluxe you can lead us off
Comment by Oilminerdeluxe on Oct 03, 2021 7:03am
2nd week of Dec. Thanks. My singing is actually worse than my ability to pick stocks that rise in value. So that might be a horrid event. I wonder if they will wait until then to give us the next newsletter. Would not mind some virus updates while we wait. But lips remain shut. 
Comment by enriquesuave on Oct 03, 2021 11:50am
Yes by August 30th they had treated a total of 24 patients, so between about November 20- Dec-7 patients 21-24 should be seen for their 90 day assessment.  My guess is in 2-3 weeks we should get Quarterly and data on #19, and 20.  Hopefully we get COVID-19 update as well. 
Comment by Oilminerdeluxe on Oct 03, 2021 12:09pm
Would be sweet indeed. Thanks.
Comment by Pandora on Oct 03, 2021 1:22pm
Any guesses on action to be taken re the 37.5 cent warrants expiring in November. Will they be allowed to expire or will the date be extended?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250